|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
WMH, APOE epsilon4 and hypertension had no significant effect on atrophy rates.
|
15961190 |
2006 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
While midlife HTN is not associated with late life cognitive impairment, midlife SBP is related to late life attention and verbal fluency impairments, particularly among ApoE4+ individuals.
|
26402768 |
2015 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
We used a mouse model of sympathetic nervous system-driven hypertension on the atherosclerotic-prone apolipoprotein E-deficient background.
|
30361420 |
2019 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We further assessed the possibility that either of these genes may interact with the apolipoprotein E gene, a known risk factor for hypertension and AD, on predicting AD.
|
10490699 |
1999 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
We examined whether nondemented stroke patients with (1) a prestroke history of hypertension and (2) APOE4 were more cognitively impaired at 3 months after stroke.
|
16051894 |
2005 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We examined contribution of three polymorphisms frequently associated with individual differences in cognition (Catechol-O-Methyl-Transferase Val158Met, Brain-Derived-Neurotrophic-Factor Val66Met, and Apolipoprotein E epsilon4) and a vascular risk factor (hypertension) in a sample of 189 volunteers (age 18-82).
|
19210038 |
2009 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Using multivariable regression models, we characterized the frequency distribution of abnormal white matter in midlife and investigated associations with hypertension and <i>Apolipoprotein E-</i>ε4 status and the impact of duration and control of hypertension.
|
27790395 |
2016 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Two risk score versions were calculated: one including age, gender, obesity, hyperlipidemia, and hypertension; and one additionally including apolipoprotein E (APOE) ε4 carrier status.
|
27143429 |
2016 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
To evaluate this effect in vivo, apolipoprotein E(-/-) mice were randomly assigned to receive standard chow, a high-cholesterol diet, or a high-cholesterol diet with hypertension induced by angiotensin II infusion for 8 weeks.
|
11435347 |
2001 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
To determine 1) age-adjusted transition probabilities to worsening physical/cognitive function states, reversal to normal cognition/physical function, or maintenance of normal state; 2) whether these transitions are modulated by sex, BMI, education, hypertension (HTN), health status, or APOE4; 3) whether worsening gait speed preceded cognition change, or vice versa.
|
28244566 |
2017 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Those with Alzheimer's disease-related cognitive impairment were younger, more likely to have a positive PiB-PET scan and carry at least one apolipoprotein E ɛ4 allele; those with subcortical vascular cognitive impairment were more likely to have hypertension, diabetes mellitus, hyperlipidaemia, prior stroke, lacunes, deep microbleeds, and carry the apolipoprotein E ɛ3 allele.
|
28335021 |
2017 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
This study shows the relevance of polymorphisms in APOB (odds ratio (OR), 1.17; 95% confidence interval (95% CI), 0.74-1.85), APOC3 (OR, 1.33; 95% CI, 0.82-2.17) and APOE (OR, 1.75; 95% CI, 1.09-2.80), as genetic risk markers for hypercholesterolemia; polymorphisms in ACE (OR, 1.68; 95% CI, 0.32-8.77) and AGT (OR, 1.74; 95% CI, 0.97-3.14) for hypertension; and in APOE*3/*4 (OR, 2.06; 95% CI, 1.70-2.51) and APOE*4/*4 (OR, 3.08; 95% CI, 1.85-5.12) as unambiguous markers of dementia.
|
29081697 |
2017 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
This review article will highlight the molecular mechanisms by which peri-menopause may influence the female brain vulnerability to AD and AD risk factors, such as hypertension and apolipoprotein E (APOE) genotype.
|
31551757 |
2019 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
These results suggest that the presence of the APOE promoter polymorphism is not a major risk factor for hypertension but that it does have some minor effect on basal blood pressure variation.
|
10821138 |
2000 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The objective of this study was to examine the association between ApoE polymorphism and prevalent hypertension in a large unselected population of older adults.
|
18297189 |
2008 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
The findings may contribute to clarify the mechanisms of development of postmenopausal hypertension and the link between RAAS and apolipoprotein E.
|
28987631 |
2017 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The findings also indicate a synergistic effect of an APOE4 allele and hypertension on the acceleration of cognitive decline.
|
22285757 |
2012 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The authors examined the risk of AD associated with the APOE-epsilon4 allele, the APOE-epsilon2 allele, smoking, alcohol consumption, history of hypertension, low educational level, estrogen replacement therapy, and history of head trauma with loss of consciousness among samples of white non-Hispanics (WNH) (392 AD patients, 202 normal subjects) and white Hispanics (WHIS) (188 AD patients, 84 normal controls).
|
10025786 |
1999 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The apolipoprotein E4 (APOE4) allele incidence and dose frequencies were increased in the AD, cCAD and HyperT groups compared to the non-HD controls.
|
8791246 |
1996 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The apolipoprotein E alleles were not associated with hypertension, obesity, smoking, or diabetes, but the epsilon 4 allele frequency was reduced in women after 60 years of age.
|
7966894 |
1994 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
The APOE-hypertension interaction was associated with a small but statistically significant increase in the rate of decline of episodic memory, verbal ability, and global cognition.
|
25672766 |
2015 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
TGF-beta(1) may cause endothelial dysfunction in apolipoprotein E-deficient (apoE(-/-)) mice via stimulation of reactive oxygen species (ROS) production by the NADPH oxidase (NOX) system and aggravate aortic and heart remodeling and hypertension.
|
20511416 |
2010 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Subjects with APOE/epsilon 4 were significantly ( P < 0.03) more frequent (19.7%) in normotensives than in hypertensives (16.9%), the estimated odds ratio for hypertension (with APOE/epsilon 4 versus without APOE/epsilon 4) being 0.83 [95% confidence interval (CI), 0.70-0.98].
|
12359980 |
2002 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Specifically, compared with normotensive women with the APOE e3/3 genotype, APOE e4 allele carriers with treated hypertension scored lower by 0.50 units (95%CI:-0.69,-0.31); however, the APOE e4 allele carriers with untreated hypertension scored lower by 1.02 units on the TICS score (95%CI:-1.29, -0.76).
|
31697783 |
2019 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
So far the major findings have included: apolipoprotein E e4, a major risk factor for AD in most populations, is also a risk factor for AD in African Americans but not for Yoruba; African Americans are at higher risk not only for AD, but also for diseases associated with increased cardiovascular risk such as hypertension, diabetes, and metabolic syndrome; African Americans have higher rates of hypercholesterolemia than Yoruba: there is an interaction between apolipoprotein E e4, cholesterol, and AD risk in both Yoruba and African Americans.
|
16917194 |
2006 |